Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
RMTI's Cash-to-Debt is ranked higher than
99% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RMTI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 31.21 Max: No Debt
Current: No Debt
Equity-to-Asset 0.63
RMTI's Equity-to-Asset is ranked higher than
50% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RMTI: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
RMTI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.59  Med: 0.64 Max: 0.92
Current: 0.63
-0.59
0.92
Interest Coverage No Debt
RMTI's Interest Coverage is ranked higher than
98% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. RMTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RMTI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 4.62
Beneish M-Score: -1.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -37.90
RMTI's Operating Margin % is ranked lower than
82% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. RMTI: -37.90 )
Ranked among companies with meaningful Operating Margin % only.
RMTI' s Operating Margin % Range Over the Past 10 Years
Min: -108.87  Med: -29.84 Max: -4.82
Current: -37.9
-108.87
-4.82
Net Margin % -36.35
RMTI's Net Margin % is ranked lower than
82% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. RMTI: -36.35 )
Ranked among companies with meaningful Net Margin % only.
RMTI' s Net Margin % Range Over the Past 10 Years
Min: -108.39  Med: -31.61 Max: -4.51
Current: -36.35
-108.39
-4.51
ROE % -35.58
RMTI's ROE % is ranked lower than
84% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. RMTI: -35.58 )
Ranked among companies with meaningful ROE % only.
RMTI' s ROE % Range Over the Past 10 Years
Min: -1304.41  Med: -34.36 Max: -8.96
Current: -35.58
-1304.41
-8.96
ROA % -23.33
RMTI's ROA % is ranked lower than
83% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. RMTI: -23.33 )
Ranked among companies with meaningful ROA % only.
RMTI' s ROA % Range Over the Past 10 Years
Min: -220.66  Med: -27.46 Max: -7.47
Current: -23.33
-220.66
-7.47
ROC (Joel Greenblatt) % -159.95
RMTI's ROC (Joel Greenblatt) % is ranked lower than
84% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. RMTI: -159.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RMTI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2678.13  Med: -260.69 Max: -52.63
Current: -159.95
-2678.13
-52.63
3-Year Revenue Growth Rate -12.90
RMTI's 3-Year Revenue Growth Rate is ranked lower than
88% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. RMTI: -12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RMTI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -23.2  Med: 2.7 Max: 32
Current: -12.9
-23.2
32
3-Year EBITDA Growth Rate -35.90
RMTI's 3-Year EBITDA Growth Rate is ranked lower than
96% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RMTI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.9  Med: -24.2 Max: 165.1
Current: -35.9
-52.9
165.1
3-Year EPS without NRI Growth Rate -35.90
RMTI's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. RMTI: -35.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RMTI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -20.6 Max: 109.9
Current: -35.9
0
109.9
GuruFocus has detected 4 Warning Signs with Rockwell Medical Inc $RMTI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RMTI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

RMTI Guru Trades in

Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
Q3 2015

RMTI Guru Trades in Q3 2015

Paul Tudor Jones 49,916 sh (+91.73%)
» More
Q4 2015

RMTI Guru Trades in Q4 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NAS:ZGNX, NAS:ALIM, AMEX:NNVC, NAS:RTRX, NAS:PRPH, NAS:TNXP, NAS:IMNP, AMEX:AXN, OTCPK:INNV, NAS:ALQA, OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB, AMEX:TXMD, NAS:AERI, NYSE:BMY, NYSE:LLY, NYSE:ABBV, NYSE:MRK, NYSE:PFE » details
Traded in other countries:RWM.Germany,
Headquarter Location:USA
Rockwell Medical Inc is a biopharmaceutical company engaged in end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.

Ratios

vs
industry
vs
history
PB Ratio 7.48
RMTI's PB Ratio is ranked lower than
89% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. RMTI: 7.48 )
Ranked among companies with meaningful PB Ratio only.
RMTI' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 7.57 Max: 950
Current: 7.48
1.73
950
PS Ratio 6.79
RMTI's PS Ratio is ranked lower than
76% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. RMTI: 6.79 )
Ranked among companies with meaningful PS Ratio only.
RMTI' s PS Ratio Range Over the Past 10 Years
Min: 0.47  Med: 2.88 Max: 15.05
Current: 6.79
0.47
15.05
EV-to-EBIT -16.15
RMTI's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. RMTI: -16.15 )
Ranked among companies with meaningful EV-to-EBIT only.
RMTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -80.4  Med: -15.1 Max: -1.2
Current: -16.15
-80.4
-1.2
EV-to-EBITDA -16.73
RMTI's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. RMTI: -16.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
RMTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1117.1  Med: -16.7 Max: -1.2
Current: -16.73
-1117.1
-1.2
Current Ratio 7.19
RMTI's Current Ratio is ranked higher than
86% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. RMTI: 7.19 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.03 Max: 12.58
Current: 7.19
0.49
12.58
Quick Ratio 5.90
RMTI's Quick Ratio is ranked higher than
84% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. RMTI: 5.90 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.63 Max: 11.68
Current: 5.9
0.35
11.68
Days Inventory 89.62
RMTI's Days Inventory is ranked higher than
65% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. RMTI: 89.62 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s Days Inventory Range Over the Past 10 Years
Min: 21.24  Med: 23.36 Max: 78.49
Current: 89.62
21.24
78.49
Days Sales Outstanding 48.78
RMTI's Days Sales Outstanding is ranked higher than
73% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. RMTI: 48.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 32.18 Max: 43.79
Current: 48.78
23.3
43.79
Days Payable 30.74
RMTI's Days Payable is ranked lower than
86% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. RMTI: 30.74 )
Ranked among companies with meaningful Days Payable only.
RMTI' s Days Payable Range Over the Past 10 Years
Min: 26.41  Med: 40.52 Max: 125.48
Current: 30.74
26.41
125.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.70
RMTI's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. RMTI: -8.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RMTI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -39  Med: -14.4 Max: 9.6
Current: -8.7
-39
9.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 16.53
RMTI's Price-to-Net-Cash is ranked lower than
64% of the 239 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.21 vs. RMTI: 16.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RMTI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.11  Med: 14.23 Max: 394
Current: 16.53
4.11
394
Price-to-Net-Current-Asset-Value 8.45
RMTI's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 512 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. RMTI: 8.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RMTI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.27  Med: 9.74 Max: 309
Current: 8.45
3.27
309
Price-to-Tangible-Book 7.62
RMTI's Price-to-Tangible-Book is ranked lower than
81% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. RMTI: 7.62 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RMTI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 7.93 Max: 98.28
Current: 7.62
2.68
98.28
Price-to-Median-PS-Value 2.36
RMTI's Price-to-Median-PS-Value is ranked lower than
89% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. RMTI: 2.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RMTI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.81 Max: 4.69
Current: 2.36
0.15
4.69
Earnings Yield (Greenblatt) % -6.19
RMTI's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RMTI: -6.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RMTI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -86.6  Med: -6.6 Max: -1.2
Current: -6.19
-86.6
-1.2

More Statistics

Revenue (TTM) (Mil) $54.25
EPS (TTM) $ -0.39
Beta1.78
Short Percentage of Float21.86%
52-Week Range $3.55 - 8.98
Shares Outstanding (Mil)52.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 61 69 72
EPS ($) -0.20 -0.05 0.03
EPS without NRI ($) -0.20 -0.05 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Rockwell Medical Sends Important Message to Richmond Brothers’ Clients: You Have the Sole Autho May 25 2017 
Rockwell Medical Encourages Shareholders Not to Be Misled by Richmond Brothers May 16 2017 
Rockwell Medical Files Investor Presentation May 10 2017 
Rockwell Medical Shareholders Express Support for the Election of David Domzalski May 09 2017 
Rockwell Medical Schedules First Quarter 2017 Earnings Call May 05 2017 
Rockwell Medical Mails Letter to Shareholders Profiling Independent Director Nominee David Domzalski May 04 2017 
Rockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress Apr 27 2017 
Rockwell Medical Files Definitive Proxy Materials Apr 21 2017 
Rockwell Medical Announces Triferic® Poster Presentations at the National Kidney Foundation (NKF) Apr 10 2017 
Rockwell Medical Files Preliminary Proxy Statement for Annual Meeting Apr 04 2017 

More From Other Websites
Rockwell Medical, Inc. breached its 50 day moving average in a Bearish Manner : RMTI-US : July 18,... Jul 18 2017
Rockwell Medical Announces Triferic® Presentation at Annual Conference on Nephrology & Urology July... Jun 28 2017
ETFs with exposure to Rockwell Medical, Inc. : June 15, 2017 Jun 15 2017
Rockwell Medical Shareholders Give Mark H. Ravich Sweeping Mandate for Change Jun 06 2017
Rockwell Medical, Inc. breached its 50 day moving average in a Bearish Manner : RMTI-US : June 2,... Jun 02 2017
Shareholders Resoundingly Vote to Support Richmond / Ravich Case for Change at Rockwell Medical Jun 01 2017
Rockwell Medical shareholders back Ravich for board seat-sources Jun 01 2017
All Three Major Proxy Advisory Firms Recommend Election of Mark H. Ravich to Rockwell Medical Board May 26 2017
Rockwell Medical Sends Important Message to Richmond Brothers’ Clients: You Have the Sole... May 25 2017
Rockwell Medical loses round in U.S. court in proxy fight May 25 2017
Court Denies Rockwell’s Motion for Preliminary Injunction against Richmond Brothers and Mark H.... May 25 2017
Glass Lewis Supports Election of Mark H. Ravich to Rockwell Medical, Inc. Board May 24 2017
ETFs with exposure to Rockwell Medical, Inc. : May 22, 2017 May 22 2017
Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting... May 22 2017
Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of... May 22 2017
ISS Supports Election of Mark H. Ravich to Rockwell Medical, Inc. Board May 22 2017
Rockwell Medical, Inc. :RMTI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Richmond Brothers and Mark H. Ravich Issue Letter to Rockwell Medical, Inc. Shareholders May 19 2017
Rockwell Medical Encourages Shareholders Not to Be Misled by Richmond Brothers May 16 2017
Rockwell Medical, Inc. – Value Analysis (NASDAQ:RMTI) : May 16, 2017 May 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}